Millennium Management LLC cut its stake in Urovant Sciences Ltd (NASDAQ:UROV) by 18.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 403,650 shares of the company’s stock after selling 91,114 shares during the period. Millennium Management LLC owned 1.33% of Urovant Sciences worth $2,660,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the stock. FMR LLC acquired a new stake in Urovant Sciences in the 3rd quarter worth approximately $14,400,000. Perceptive Advisors LLC boosted its stake in Urovant Sciences by 35.2% in the 4th quarter. Perceptive Advisors LLC now owns 625,359 shares of the company’s stock worth $3,915,000 after purchasing an additional 162,700 shares in the last quarter. BlackRock Inc. acquired a new stake in Urovant Sciences in the 3rd quarter worth approximately $4,574,000. Sphera Funds Management LTD. boosted its stake in Urovant Sciences by 30.5% in the 4th quarter. Sphera Funds Management LTD. now owns 214,030 shares of the company’s stock worth $1,410,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Man Group plc acquired a new stake in Urovant Sciences in the 3rd quarter worth approximately $300,000. Institutional investors own 22.77% of the company’s stock.
UROV opened at $8.05 on Monday. Urovant Sciences Ltd has a 12-month low of $4.05 and a 12-month high of $14.49.
A number of research firms recently commented on UROV. Zacks Investment Research upgraded shares of Urovant Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 9th. HC Wainwright started coverage on shares of Urovant Sciences in a research report on Monday, March 11th. They set a “buy” rating and a $28.00 price target for the company. Finally, SunTrust Banks started coverage on shares of Urovant Sciences in a research report on Friday, March 15th. They set a “buy” rating and a $24.00 price target for the company. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $21.13.
Urovant Sciences Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Story: How to find the components of the quick ratio
Want to see what other hedge funds are holding UROV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urovant Sciences Ltd (NASDAQ:UROV).
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.